EGFR and non-small cell lung carcinoma: For example, EGFR (epidermal growth factor receptor) inhibitors were developed about twenty years ago and approved in Japan as molecular-targeted therapies for non-small-cell lung cancer (NSCLC); since then, a variety of EGFR inhibitors have been developed worldwide [1].